Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02707887
Other study ID # 15-0815
Secondary ID R01DA026424
Status Completed
Phase N/A
First received
Last updated
Start date January 2016
Est. completion date December 2020

Study information

Verified date January 2021
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to: 1. test the effect of a smartphone enhanced LETS ACT (LETS ACT-SE) on frequency of substance use 2. use functional magnetic resonance imaging (fMRI) to test the relationship between neuromarkers of reward sensitivity on frequency of substance use.


Description:

Comorbid substance use disorder (SUD) and depression is highly prevalent and associated with elevated rates of post treatment relapse to substance use, HIV risk behavior, and associated poor mental and physical health outcomes. Further, rates of substance use and depression disproportionately affect minority groups and those living in poverty. Although efficacious, the often complex, specialized nature of CBT poses problems in its integration into substance use treatment programs. Budget cuts for mental health and substance use treatment both nationally and in the state of North Carolina, reduce availability of publically funded treatment programs and staff to patient ratios. To address this limitation, a behavioral activation (BA) treatment, the Life Enhancement Treatment for Substance Use (LETS ACT), was developed to treat depressive symptoms among a predominantly African American sample of low income illicit drug users currently receiving residential substance use treatment. Collectively, two Stage I studies and 1 year follow-up data from the investigators Stage II R01DA026424 indicate that compared to a control condition, LETS ACT is associated with significantly better outcomes for treatment retention, post treatment abstinence, HIV sexual risk behavior, depressive symptoms, and environmental reward. Although these strong outcomes suggest that LETS ACT may be ready for a Stage III dissemination trial, it is of note that there was a significant indirect effect of LETS ACT homework compliance on post treatment substance use and HIV sexual risk behavior via the theoretically proposed BA mechanism of action, environmental reward. In the context of limited access to care, these findings point to the need to identify cost-effective delivery-vehicles to increase treatment engagement outside of clinician sessions. Further, identifying neuroscience based biomarkers (neuromarkers) underlying key theoretical aspects of BA (i.e., reward sensitivity), and their relation to heterogeneity in BA treatment response among substance users with depression, are critical for the identification of accurately targeted interventions.


Recruitment information / eligibility

Status Completed
Enrollment 206
Est. completion date December 2020
Est. primary completion date December 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Between 18 and 55 - Meet criteria for DSM-V substance use disorder - Elevated depressive symptoms (BDI = 14) Exclusion Criteria: - Limited mental competency (MMSE < 23) - Psychosis - The use of psychotropic medication for < 3 months - The inability to give informed, voluntary, written consent to participate

Study Design


Intervention

Behavioral:
LETS ACT
The Life Enhancement Treatment for Substance Use (LETS ACT)
LETS ACT-SE
Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
Treatment as Usual
Participants will receive the treatment typically provided to patients at the substance use treatment facility.

Locations

Country Name City State
United States University of North Carolina at Chapel Hill Chapel Hill North Carolina
United States Southlight Healthcare Raleigh North Carolina

Sponsors (2)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Timeline Followback (TLFB) The Time Line Follow Back is a self-report measure of drug and alcohol use. TLFB will be assessed from baseline to a 12-month follow up period.
Secondary Behavioral Activation for Depression Scale (BADS) The BADS is a 25-item self-report measure of overall level of activity involvement BADS will be assessed from baseline to a 12-month follow up period.
Secondary Reward Probability Index (RPI) The RPI is a 20-item self-report measure used to assess environmental reward and punishment. RPI will be assessed from baseline to a 12-month follow up period.
Secondary Beck Depression Inventory-II (BDI-II) The Beck Depression Inventory is a 21-item self-report measure of depressive symptoms BDI-II will be evaluated from baseline to a 12-month follow up period
Secondary Daily Goals Form The Daily Goals Form is used to measure Treatment Engagement. Baseline to a 3-months post treatment.
Secondary Texas Christian University (TCU) HIV/AIDS Risk Assessment Form The TCU is a self-structured interview that measures HIV risk behavior in the domains of drug use and sex TCU will be assessed from baseline to a 12-month follow up period.
Secondary Urinalysis Urinalysis is a biological measure of substance use. Urinalysis is assessed from post treatment to a 12-month follow up period
Secondary Breathalyzer Breathalyzer is a biological measure of alcohol use. Breathalyzer will be assessed from baseline to a 12-month follow up period.
Secondary Short Form Health Survey (SF-12) The SF-12 is a 12-item self-report measure of mental and physical health-related functioning. SF-12 will be assessed from baseline to a 12-month follow up period.
See also
  Status Clinical Trial Phase
Completed NCT01316926 - Paxil CR Bioequivalence Study Brazil Phase 1
Recruiting NCT06187454 - Transcranial Direct Current Stimulation for Depression N/A
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Recruiting NCT05768126 - Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine Phase 4
Completed NCT03219879 - Telephone-administered Relapse Prevention for Depression N/A
Recruiting NCT06038721 - Unified Protocol: Community Connections N/A
Completed NCT03043560 - Study to Treat Major Depressive Disorder With a New Medication Phase 2
Completed NCT04091139 - Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong Phase 2/Phase 3
Completed NCT00069459 - Seasonal Affective Depression (SAD) Study Phase 1
Recruiting NCT05503966 - Combining Antidepressants and Attention Bias Modification in Depression N/A
Recruiting NCT03001245 - Interpersonal Counseling (IPC) for Treatment of Depression in Adolescents N/A
Completed NCT02939560 - TMS for Adults With Autism and Depression N/A
Completed NCT02542891 - European Comparative Effectiveness Research on Internet-based Depression Treatment N/A
Completed NCT02452892 - Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD) N/A
Completed NCT02224508 - Evaluation of a Health Plan Initiative to Mitigate Chronic Opioid Therapy Risks N/A
Completed NCT02306551 - Well Being And Resilience: Mechanisms of Transmission of Health and Risk
Withdrawn NCT02238730 - Ultrabrief Right Unilateral and Brief Pulse Bitemporal Electroconvulsive Therapy N/A
Completed NCT01407575 - Buprenorphine for Treatment Resistant Depression Phase 3
Completed NCT01597661 - Bupropion & Cardio Birth Defect (Slone) N/A
Completed NCT01093053 - Mind-Body Skills Groups for the Treatment of War Zone Stress in Military and Veteran Populations N/A